Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2014

Open Access 01-05-2014 | Oral presentation

Regulated intratumoral expression of IL-12 as a basis for combination therapy in melanoma

Authors: John J Nemunaitis, Gerald P Linette, Omid Hamid, Sanjiv S Agarwala, Alexander Starodub, Lei Sun, Francois Lebel, John A Barrett, Jonathan Lewis

Published in: Journal of Translational Medicine | Special Issue 1/2014

Login to get access

Excerpt

Major obstacles for the development of immunotherapeutics are the ability of tumors to escape the immune system coupled with toxicity associated with systemic administration. To overcome these challenges, we have developed an adenoviral vector, Ad-RTS-IL-12 (AD), administered intratumorally under control of the RheoSwitch Therapeutic System® gene expression platform. Expression of IL-12 mRNA and IL-12 protein is tightly regulated by the oral administration of a small molecule activator ligand, veledimex (AL). …
Metadata
Title
Regulated intratumoral expression of IL-12 as a basis for combination therapy in melanoma
Authors
John J Nemunaitis
Gerald P Linette
Omid Hamid
Sanjiv S Agarwala
Alexander Starodub
Lei Sun
Francois Lebel
John A Barrett
Jonathan Lewis
Publication date
01-05-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue Special Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-S1-O11

Other articles of this Special Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue

Oral presentation

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma

Oral presentation

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters

Oral presentation

Revealing cancer initiating cells in metastatic melanomas by harnessing the host′s anti tumor humoral immune mechanisms

Oral presentation

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification

Poster presentation

Natural immunomodulator preimplantation factor PIF affected cancer growth in malignant melanomas

Oral presentation

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits